Fosun International Ltd Stock Price, News & Analysis

Fosun (OTC:FOSUF) marked its eighth consecutive year at the China International Import Expo on November 5, 2025, showcasing oncology, neurology, kidney disease, and supportive-care innovations.

Key highlights include the China debut of the Marie Upright Particle Therapy System (FDA approved July 2025), progress for CAR-T therapy Yi Kai Da (>190 treatment centers; >1,000 lymphoma patients treated; included in 110+ urban customized and 80+ commercial insurances), NMPA acceptance of a second CAR-T in Sept 2025, and >480 Da Vinci surgical systems installed by Sept 2025.

Fosun (OTC: FOSUF) announced the launch of the First International Jewelry Fashion Theme Month in Shanghai on October 30, 2025, coinciding with the 2025 Shanghai Haute Couture Week.

The event follows the May 16, 2025 inauguration of the Shanghai International Jewelry & Style District, unveiled an official logo, appointed 6 expert panel members, accepted 15 key brands with Golden Keys, and recorded 2 cooperation agreements with Zijin Mining Group Gold & Jewelry and the Gem & Jewelry Trade Association of China.

The Grand Yuyuan Cultural Area — cited as the district core — draws over 40 million annual visitors and will host new store openings, fashion shows, and six district initiatives aimed at boosting brand incubation, infrastructure, and industry integration.

Fosun (OTC:FOSUF) outlined its innovation-driven globalization strategy at the 2025 Sustainability Global Leaders Conference on October 16, 2025. Leadership highlighted biopharma, consumer, tourism and insurance initiatives that combine R&D, regulatory reach and AI to expand global impact.

Key facts: HANSIZHUANG is approved in nearly 40 countries and has benefited >110,000 patients; a Phase III perioperative gastric cancer trial met its primary endpoint on Oct 9, 2025. Henlius has filed >800 regulatory applications with >600 approvals. Fosun reported >RMB1bn BD cash inflows in H1 with +280% YoY growth. Fosun cites MSCI ESG rating AA and WHO prequalification for its artesunate product.

Fosun International (OTC:FOSUF) saw its S&P Global Corporate Sustainability Assessment (CSA) score rise to 72 points on Oct 9, 2025, up from 70 in 2024, retaining its industry lead.

The company scored 75 Environmental, 72 Social, and 70 Governance & Economic, was included in the S&P Sustainability Yearbook 2025 (top 1% China edition), and maintains an MSCI AA rating and HSI sustainability rating AA-. Fosun reported three consecutive Climate Information Disclosures and cited large social-health contributions, including support for 25,000 rural doctors and >broad use of artesunate in >84 million severe malaria patients.

Fosun International (OTC:FOSUY) has maintained its AA- rating in the 2025 Sustainability Ratings by Hang Seng Indexes Company for the third consecutive year. The company has also been selected as a constituent of the Hang Seng Corporate Sustainability Benchmark Index for the sixth consecutive year.

The company ranked in the top 10% among 528 Hong Kong-listed companies in four key areas: Corporate Governance, Environment, Consumer Issues, and Community Involvement. Fosun International maintains strong ESG credentials, including an MSCI ESG rating of AA and ranks in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment.

Fosun International (OTC:FOSUY) has been recognized in Fortune China's 2025 "Most Admired Chinese Companies" Industry Star List, highlighting its excellence in ESG, employee responsibility, and stakeholder value creation.

The company achieved significant milestones in H1 2025, including the development of HLX43, the world's first PD-L1-targeting antibody-drug conjugate in Phase II trials, and the expansion of Yi Kai Da cancer therapy to over 200 treatment centers across 28 provinces. The company's artesunate injection has treated over 84 million malaria patients globally, while its Rural Doctors Program has supported 25,000 rural doctors, benefiting 16.34 million rural residents.

Fosun maintains strong ESG performance, ranking in the top 1% in S&P Global's Sustainability Yearbook 2025 (China Edition) and securing inclusion in the FTSE4Good Index Series for the fourth consecutive year.

Fosun International (OTC:FOSUY) presented its H1 2025 interim results, highlighting significant achievements in innovation and global expansion. The company reported total revenue of RMB87.28 billion, with overseas revenue accounting for 53% of total revenue. The Group's industrial operation profit reached RMB3.15 billion, while profit attributable to owners was RMB661.2 million.

The company's four core subsidiaries - Fosun Pharma, Yuyuan, Fosun Insurance Portugal, and Fosun Tourism Group - contributed 73% of total revenue at RMB63.61 billion. Management emphasized its focus on innovation, particularly in biopharmaceuticals, and its commitment to debt reduction, targeting interest-bearing debt of RMB60 billion or less while maintaining a current healthy debt-to-capital ratio of 53%.

Fosun International (OTC:FOSUY) Chairman Guo Guangchang outlined the company's strategic vision during its 2025 interim results presentation, emphasizing continued investment in biopharmaceuticals and focus on established advantageous sectors. The company has made significant breakthroughs in its pharmaceutical segment, with a robust pipeline of innovative drugs including Henlius products and Fosun Kite's CAR-T therapy.

Highlighting Fosun's commitment to global expansion, Guangchang emphasized the company's dedication to building global R&D, clinical, and sales capabilities. The chairman noted that establishing competitive strength requires long-term investment, citing Henlius's RMB10 billion investment over 15 years and the recent profitability of its insurance ventures.

The company maintains its vision of helping people live healthily to age 121, with a particular focus on making cancer curable through comprehensive treatment approaches combining drugs, devices, and multi-molecule therapies.

Fosun International (OTC:FOSUY) released its 2025 interim results, reporting total revenue of RMB87.28 billion and profit attributable to owners of RMB661.2 million. The company's four core subsidiaries generated RMB63.61 billion in revenue, representing 73% of total revenue.

Key highlights include RMB3.6 billion investment in technology and innovation, with significant breakthroughs in innovative drugs, particularly HLX43's global Phase II clinical trials. Overseas revenue reached RMB46.67 billion, accounting for 53% of total revenue. The company maintained a healthy debt ratio of 53% and received a "Stable" outlook from S&P.

Notable achievements include Fosun Pharma's 38.96% profit growth, Fosun Insurance Portugal's 27.6% net profit increase, and FTG's record business volume of RMB9.53 billion with 42% adjusted net profit growth year-on-year.